OPKO Health, Inc. (OPK)

Market Cap	913.56M -17.9%
Revenue (ttm)	606.88M -14.9%
Net Income	-225.68M
EPS	-0.30
Shares Out	767.70M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,272,384
Open	1.160
Previous Close	1.160
Day's Range	1.160 - 1.200
52-Week Range	1.110 - 1.870
Beta	1.52
Analysts	Buy
Price Target	2.03 (+70.59%)
Earnings Date	Apr 29, 2026

About OPK

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune syst...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Nov 2, 1995
• Employees: 2,275
• Stock Exchange: NASDAQ
• Ticker Symbol: OPK
• Website: https://www.opko.com

Financial Performance

In 2025, OPKO Health's revenue was $606.88 million, a decrease of -14.90% compared to the previous year's $713.14 million. Losses were -$225.68 million, 324.0% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for OPK stock is "Buy." The 12-month stock price target is $2.03, which is an increase of 70.59% from the latest price.

Price Target

$2.03

(70.59% upside)

Analyst Consensus: Buy